Biofourmis Exit Candidate

Employees 250+
Primary contact

🏦 Potential exit path: SPAC, M&A
Biofourmis is developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. The company's Biovitals (FDA-cleared) AI-powered health analytics platform is made to predict clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics' product pipeline across multiple therapeutic areas — including heart failure, oncology, acute coronary syndrome, COPD and chronic pain.
Employees 250+
Primary contact

Funding πŸ’°

Total $143.6M
Last round πŸ”— $100M
Series C
September 3, 2020.
Select investors SoftBank Vision Fund, Sequoia Capital, Openspace Ventures, EDBI, Aviva Ventures

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Made two acquisitions in the past: Gaido Health from Takeda Pharmaceuticals (April 2020 - to expand in the oncology space) and Switzerland-based Biovotion AG (November 2019 - developer of a clinical-grade wearable biosensor platform)
  • Biofourmis' BiovitalsHF solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the FDA πŸ”—
  • The company's AI-enabled remote monitoring platform has been tested with COVID-19 patients in Singapore and Hong Kong πŸ”—
  • As of May 2020, Biofourmis got a new CFO - Matt Borowiecki, who has a decade of experience in investment banking (preparing to go public?) πŸ”—
  • Also, could be an attractive M&A target for Big Pharma or a bigger digital therapeutics company
  • Similar companies: Better Therapeutics, Pear Therapeutics
Last update: September 6, 2021